Clinical Trial Update: Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency [Phase 3]

View source ↗

Summary

Phase 3 trial investigating GC5107 (immune globulin intravenous) in subjects with primary humoral immunodeficiency completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Humoral Immunodeficiency
• Immunologic Deficiency Syndromes

Drugs mentioned

• GC5107 (immune globulin intravenous (human))

Snippet

Sponsor: Green Cross Corporation | Conditions: Immunologic Deficiency Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2022-10-28